肝动脉化疗、栓塞治疗原发性肝癌的疗效分析

Therapeutic Effects of Hepatic Arterial Infusion Chemotherapy and Embolization in the Treatment of Primary Hepatic Carcinoma

肝动脉化疗、栓塞为不能手术切除的肝癌的首选疗法。本文系统分析经介入放射治疗的192例原发性肝癌随访10～52个月的结果,总疗效为:症状缓解者72.9％,显效26.0％,有效51.0％,α-FP下降者60.8％,治疗后1、2、3年生存率分别为52.1％、24.3％、15.1％,平均生存期13.8月,最长已存活52月。其中,108例栓塞治疗组的1、2、3年生存率分别为62.3％,38.2％。25.3％,平均生存期15.4月。对影响疗效的有关6个因素进行对比性分析,认为无或伴轻度肝硬化、早中期、单个肿块、大小<10×10cm^2、无门脉癌栓行栓塞治疗者,其临床疗效明显优于对照组。

Hepatic arterial infusion chemotherapy and embolization (HAI and HAE) are the first selective methods in the treatment of unresectable primary hepatic carcinoma. 192 patients were followed up for ten to fifty-two mouths after HAI and HAE, the general therapeutic effects were:Symptotic relief in 72.9%, complete response in 26.0%, partial response in 51.0% , α-FP decreasing in 60. 8%, 1-, 2-, 3-year survival rate in 52.1%,24.3%, 15.1%, the mean survival time in 13.8 months, the longest survival period in 52 months. In the HAE group (108 cases), 1-, 2-, 3-year survival rate respectively was 62.3%,38.2% ,25.3%,the mean survival time was 15.4 months. Six factors influencing therapeutic effects were analyzed con-trolly, results revealing that the tumor without or with mild cirrhosis, early or moderate stage, single and the tumor100 cm2 in size, no cancerous emboli in portal vein, embolizated treatment, had better effects than the contrast group.